Tenders Are Invited For Conclusion Of A Non-Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Raltegravir, Atc J05ax08 For The Period November 1St, 2023 - October 31St, 2025
Tenders Are Invited For Conclusion Of A Non-Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Raltegravir, Atc J05ax08 For The Period November 1St, 2023 - October 31St, 2025
Conclusion Of A Non-Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Raltegravir, Atc J05ax08 For The Period November 1St, 2023 - October 31St, 2025. Section 130A Paragraph 8 Sgb V Enables Health Insurance Companies And Pharmaceutical Companies To Conclude Framework Discount Agreements For The Medicines To Be Supplied At The Expense Of The Statutory Health Insurance Companies. With Regard To The Relevant Legal Regulations For The Awarding Of Public Contracts, A Regular Process Of Active Ingredient-Related, Formal Award Procedures Takes Place In Accordance With The Regulations Of Part 4 Of The Gwb By Dakgesundheit. For Medicinal Products To Be Specified By The Bidder In Annex 2 To The Contract In Relation To The Above. Active Ingredient, Raltegravir, Atc J05ax08, Dakgesundheit Intends To Conclude Drug Discount Agreements With As Many Interested Pharmaceutical Companies As Possible Until New Drug Discount Agreements Come Into Force. A Discount Contract In The Form Of An Approval Model For The Above-Mentioned. The Active Ingredient Comes Into Force For The First Time On November 1St, 2023 And Ends On October 31St, 2025. Regardless, It Ends Automatically When The Exclusive Contract Comes Into Force.
We takes all possible care for accurate & authentic tender information, however Users are requested to refer Original source of Tender Notice / Tender Document published by Tender Issuing Agency before taking any call regarding this tender.
